logo
Share SHARE
FONT-SIZE Plus   Neg

Lorus Therapeutics Q3 Loss Narrows - Quick Facts

Canadian biopharmaceutical company Lorus Therapeutics Inc. (LOR.TO,LRUSF.PK) posted a narrower loss in the third quarter.

The company posted third-quarter net loss of C$1.0 million or C$0.05per share, narrower than than C$1.5 million or C$0.10 per share last year. Lorus Therapeutics attributed the wider net loss mainly to higher general and administrative, and research and development expenditures.

The company did not generate any revenues in both the quarters.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
German telecom giant Deutsche Telekom AG reported Wednesday that its first-quarter net profit quadrupled on hefty stake sale gain. Revenues also increased on US strength, while domestic revenues were weak. Royal Dutch Shell reported Wednesday a pre-tax loss in its first quarter, while CCS earnings plunged from last year mainly on weak revenues. Oil and gas production increased but that was offset by lower prices. Further, the company announced dividend, and warned on second-quarter earnings. Shares of French lender Societe Generale SA were gaining around 4 percent in the early morning trading in Paris after the company reported Wednesday higher profit in its first quarter, even as net banking income was weak. Looking ahead, Chief Executive Officer Frédéric Oudéa said, "With a sound balance sheet and robust solvency ratios, the Group is confident about its outlook for 2016,..
comments powered by Disqus
Follow RTT